Essay Undergraduate 567 words

Individualized Drug Therapy: Personalized Medicine Approaches

~3 min read

Abstract

This paper examines the necessity of individualized drug therapy in modern medicine, explaining the biological, genetic, and social factors that cause patients to respond differently to the same medications. The paper discusses how allergies, genetic variation, and psychological factors influence treatment outcomes, and reviews evidence from clinical trials—particularly the FDA's 2004 warning about antidepressant-induced suicidality in adolescents. It then surveys contemporary approaches to personalization, including therapeutic drug monitoring and pharmacogenomics, which use genetic profiling to predict drug responses and optimize treatment efficacy while minimizing toxicity.

📝 How to Write This Type of Paper Writing guide — click to expand

▼

What makes this paper effective

Grounded in concrete clinical examples (pain management, diabetes, antidepressants) that illustrate abstract concepts of variable drug response
Uses a specific, well-documented case (FDA's 2004 antidepressant warning) to anchor the discussion in real regulatory science
Integrates multiple dimensions of variation—biological, genetic, allergic, psychological, social—to show the complexity of the problem
Acknowledges the limits of current knowledge ("poorly understood") while pointing toward emerging solutions

Key academic technique demonstrated

The paper employs a problem-solution structure: it establishes why uniform drug therapy fails (varied responses across patients) through multiple lines of evidence, then progressively introduces more sophisticated approaches to address that problem. It also demonstrates careful integration of direct quotations from authoritative sources (FDA guidance, peer-reviewed pharmacology) to ground claims in established evidence rather than speculation.

Structure breakdown

The essay opens with three interconnected explanations for variability: physical chemistry, social/psychological factors, and allergies. It then pivots to clinical trial evidence, using the antidepressant case as a bridge to more systematic approaches. The final section categorizes contemporary methods by sophistication level—from simple antibiotic selection to pharmacogenomics—and projects how genetic profiling may enable precision medicine for specific population groups.

Patient responses to drug therapy can vary widely between individuals. For example, not all patients find their pain alleviated by the same doses of analgesics. Some patients become suicidal when taking antidepressants rather than finding their symptoms eased. This variation stems from each person's unique physical chemistry, as well as their social and psychological needs, making individualized drug therapy essential. The social and psychological component must not be minimized in this context. Consider diabetic patients who struggle to regulate their blood sugar with a complex insulin regimen; any modifications that simplify their treatment might prove extremely helpful in ensuring glucose stability and improving compliance with therapy.

Another component driving different drug response mechanisms involves allergies. Allergies to penicillin, sulfate drugs, eggs, and other substances represent a long list of potentially adverse reactions that patients can experience with medications that are otherwise harmless to non-sufferers. The reasons for different responses among patients can be extremely varied and difficult to predict. Just as all individuals have different genetic makeups, so too do patients have different responses to the same medications. Genetic variation fundamentally shapes how the body processes and responds to drugs, explaining why a treatment effective for one person may prove ineffective or dangerous for another.

Clinical drug trials can be helpful in predicting who will and who will not respond in a specific manner to certain drugs. Adolescents, in particular, have been found to be prone to suicidal ideation after being prescribed antidepressants. Following a thorough and comprehensive review of all available published and unpublished controlled clinical trials of antidepressants in children and adolescents, the U.S. Food and Drug Administration (FDA) issued a public warning in October 2004 about an increased risk of suicidal thoughts or behavior (suicidality) in children and adolescents treated with SSRI antidepressant medications. The reasons why antidepressants have such an effect on some adolescents remain poorly understood, but the observed effect was significant enough for the FDA to take regulatory action and inform the medical community.

You’re 58% through this paper. Sign up to read the full paper.

130,000+ paper examples AI writing assistant Citation generator Cancel anytime

Key Concepts in This Paper

Individualized drug therapy Pharmacogenomics Drug response variation Personalized medicine Therapeutic drug monitoring Genetic profiling Clinical trials SSRI antidepressants Population-specific treatment Drug efficacy optimization